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Abstract
Background: Birt-Hogg-Dubé syndrome is a genetic syndrome caused by mutations in the FLCN gene. The main
symptoms are lung bullae and pneumothorax, benign and malignant kidney tumors, and facial fibrofolliculoma. The
risk of pneumothorax is considerable between ages 20–40 years, but decreases markedly after this age range and
first-time pneumothorax after age 50 years is rare. Fibrofolliculomas usually occur between ages 35 and 45 years,
while the risk for kidney cancer increases steadily with age, starting in young adulthood. However, we demonstrate
here that within the same family patients might develop symptoms significantly before or after the usual age
range, obscuring the typical clinical pattern and delaying diagnosis.
Case presentation: The 43 year old index patient had a history of lung bullae and recurrent pneumothoraces
starting 14 years earlier. His father (age 83 years) and one of the paternal uncles experienced their first
pneumothorax unusually late after the age of 60 years. The uncle subsequently had four more pneumothoraces,
and was diagnosed with kidney in his early 70s. Considerable differences in age of onset were also observed with
regard to facial fibrofolliculomas that both paternal uncles developed very early around age 20 years, but which the
father only started to show in his eighth decade. Birt-Hogg-Dubé syndrome was finally diagnosed when the index
patient started to develop fibrofolliculomas within the typical age range.
Conclusions: The family described here illustrates that Birt-Hogg-Dubé syndrome can be difficult to recognize, if
presenting with considerable intrafamilial clinical variability. With a life-time kidney cancer risk of about 14–35% the
consequences of delayed diagnosis might be grave for the affected family members. The possibility of Birt-Hogg-Dubé
syndrome should therefore be taken into consideration in apparently sporadic patients presenting with lung bullae
and pneumothorax.
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Background
Birt-Hogg-Dubé syndrome (BHDS) is a genetic cancer
syndrome characterized by fibrofolliculomas, lung bullae
with the risk of spontaneous pneumothorax, and benign
or malignant kidney tumors. The syndrome is caused by
mostly truncating mutations in the FLCN gene that en-
codes folliculin, a putative tumor suppressor protein [1].
The clinical expression shows inter- and intrafamilial
variability, but the onset of symptoms usually follows an
age-dependent pattern. Lung cysts are commonly found
(in 85% of patients) and peumothoraces (often recur-
rent) affect about 25–30% of patients [2]. After age
50 years peumothoraces are rather rare in BHDS pa-
tients. Starting in young adulthood, the risk for renal
cancer steadily increases with age, leading to an average
cumulative life time risk of 14–35% [3–5]. The majority
of patients (about 80%) develop fibrofolliculomas which
are mostly located on the face but can also be found on
the neck and the upper trunk [6–8]. In most families the
autosomal mode of inheritance is obvious, because the
onset of symptoms between young adulthood and mid-
dle age ensures that patients have personal knowledge of
affected relatives in one or more previous generations.
The BHDS family we describe here demonstrates that
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the mode of inheritance, and therefore the cancer risk,
might be obscured by family members presenting with
an unusual late onset of symptoms.
Case presentation
The index patient (III6, Fig. 1) was referred to our BHD
interdisciplinary outpatient clinic at age 43 years, after
he had suffered from more than five pneumothoraces
caused by rupture of lung bullae starting at age 29 years
(Fig. 2). Facial fibrofolliculoma began to occur at the age
of 41 years. Results of screening examinations including
computer tomography of kidneys, colonoscopy and
ultrasonography of the thyroid gland were normal. The
family’s medical history was obtained from the index pa-
tient. His only son (IV1), 15 years of age, is reportedly
healthy, but - in agreement with German law - hasn’t
been genetically tested yet. The index patient’s father
(age 83 years) (II9) had his first and so far only pneumo-
thorax at age 61 years. He noticed facial fibrofolliculo-
mas for the first time 2–3 years ago around age 80 years.
He suffers from chronic renal insufficiency stage III but
has no known kidney tumors. Two of the father’s broth-
ers (II4, II7) reportedly have multiple facial fibrofollicu-
lomas since age 20 years. One of them (II7) had five
spontaneous pneumothoraces starting after age 60 years
and was diagnosed with kidney cancer and prostate can-
cer in his early 70s. The father also has four siblings
(II1–2, II5, II8) not showing any BHDS symptoms. It is
unknown, if pneumothorax or facial fibrofolliculomas
occurred in the grandparents generation. The medical
history of the index patient’s maternal family (II10) was
unremarkable. Both sides of the family are of German
origin. The CARE guidelines were followed in reporting
this case.
Mutation screening of the FLCN complete coding re-
gion and adjacent intronic sequences was performed by
PCR and subsequent Sanger sequencing following stand-
ard protocols. For each PCR 50–100 ng DNA were amp-
lified using the AmpliTAq Gold kit (Thermo Fisher
Scientific, Dreieich, Germany) and the amplification
products were subsequently purified by Quiagen PCR
purification kit (Quiagen, Hilden, Germany). Amplicons
were sequenced with the 3500 Genetic Analyser
(Thermo Fisher Scientific, Dreieich, Germany). Sequen-
cing of the FLCN gene in the index patient showed het-
erozygosity for the mutation c.1285dupC
(p.His429ProfsX27) within exon 11 (Fig. 3).
Discussion and conclusions
The index patient has been suffering from recurrent
pneumothorax for 14 years before the diagnosis of
BHDS was made. This delay most likely had different
reasons, mainly due to the the fact that BHDS is still
one of the lesser known inherited syndromes. However,
the untypical family history certainly contributed to the
delay, in particular the unusually late manifestation of
pneumothorax in the paternal generation. Pneumo-
thorax is often the first clinically recognized symptom in
BHDS patients, typically occurring between age 20 and
40 years [3, 6]. The likeliness for pneumothorax in
BHDS patients markedly decreases in the second half of
life. A first-time pneumothorax in the sixth decade, as
happened twice in the family presented here (II7, II9),
has rarely been reported in BHDS patients [9]. Another
factor contributing to the delay in diagnosis was the
atypical age of onset regarding fibrofolliculomas. These
benign skin tumors mostly start to appear between the
ages 35 and 45 years, often slowly but steadily increasing
in numbers during subsequent years [6, 10]. In both pa-
ternal uncles (II4, II7) these benign skin tumors oc-
curred at the unusually early age of 20 years, while the
index patient’s father only started to develop them at a
very advanced age. Taken together, affected family
Fig. 1 Pedigree of BDHS family. The index patient is marked by an
arrow. Black symbol, BHDS confirmed by mutation analysis; grey
symbols, clinical suspicion of BHDS
Fig. 2 Chest computed tomography scan from the index patient.
Bilateral pneumothorax (large arrows) and lung bullae (small arrows)
are indicated. The pneumothorax is mostly localized in the basal
parts of the chest cavity due to previous pleurodesis treatment
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members showed a considerable variation in both age of
onset and clinical course, rendering it particularly diffi-
cult to recognize the inheritability of the condition. The
possibility of BHDS was only taken into consideration,
when the index patient started to develop fibrofolliculo-
mas at a typical age. As a consequence of the delay in
diagnosis the affected family members remained un-
aware of their high or elevated tumor risk and their need
for regular kidney cancer screening for many decades.
There is no evidence that the intrafamilial variation
demonstrated by the index patient and his relatives
can be explained by genotype-phenotype correlation.
The mutation found in our family, c.1285dupC, is lo-
cated in a mutational hotspot in exon 11 and ac-
counts for 25–44% of all FLCN mutations [11–13].
Patients with this mutation therefore had a major im-
pact on published clinical descriptions from which
the above cited typical onset ages of BHD symptoms
were taken. The family described here represents an
example of the wide age range at which clinical mani-
festations can occur. It is likely that the clinical
course is modulated by other, unknown genetic or
non-genetic factors. The identification of such modi-
fying factors is a challenge that will require further
recruitment of BHDS families presenting with unusual
clinical histories.
The inherited syndrome BHDS can be difficult to
diagnose, if presenting with significant intrafamilial
clinical heterogeneity. The family described here dem-
onstrates that monosymptomatic expression or mani-
festation of symptoms far outside the typical age
range might delay diagnosis. Considering the cumula-
tive life time risk of 14–35% for kidney tumors the
consequences of such a delay are potentially serious
for the affected family members. As demonstrated by
Park et al. [13], the diagnosis of BHDS should always
be taken into consideration in apparently healthy
younger adults presenting with a combination of atyp-
ically localized lung bullae and pneumothorax, even
in the absence of a typical family history.
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